Brosen K - Search Results

1

Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands.

Halling J, Petersen MS, Grandjean P, Weihe P, Brosen K. Halling J, et al. Among authors: brosen k. Pharmacogenet Genomics. 2008 Mar;18(3):209-12. doi: 10.1097/FPC.0b013e3282f5106e. Pharmacogenet Genomics. 2008. PMID: 18300942

2

CYP2D6 genotype determination in the Danish population.

Brøsen K, Nielsen PN, Brusgaard K, Gram LF, Skjødt K. Brøsen K, et al. Eur J Clin Pharmacol. 1994;47(3):221-5. doi: 10.1007/BF02570501. Eur J Clin Pharmacol. 1994. PMID: 7867674

3

A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.

Brøsen K, de Morais SM, Meyer UA, Goldstein JA. Brøsen K, et al. Pharmacogenetics. 1995 Oct;5(5):312-7. doi: 10.1097/00008571-199510000-00007. Pharmacogenetics. 1995. PMID: 8563772

4

The pharmacogenetics of codeine hypoalgesia.

Sindrup SH, Brøsen K. Sindrup SH, et al. Among authors: brosen k. Pharmacogenetics. 1995 Dec;5(6):335-46. doi: 10.1097/00008571-199512000-00001. Pharmacogenetics. 1995. PMID: 8845855 Review.

5

Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.

Madsen H, Hansen TS, Brøsen K. Madsen H, et al. Among authors: brosen k. Pharmacogenetics. 1996 Dec;6(6):513-9. doi: 10.1097/00008571-199612000-00004. Pharmacogenetics. 1996. PMID: 9014200

6

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

Christensen PM, Gøtzsche PC, Brøsen K. Christensen PM, et al. Among authors: brosen k. Eur J Clin Pharmacol. 1997;51(5):389-93. doi: 10.1007/s002280050219. Eur J Clin Pharmacol. 1997. PMID: 9049580

7

Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity.

Bathum L, Andersen-Ranberg K, Boldsen J, Brøsen K, Jeune B. Bathum L, et al. Among authors: brosen k. Eur J Clin Pharmacol. 1998 Jul;54(5):427-30. doi: 10.1007/s002280050487. Eur J Clin Pharmacol. 1998. PMID: 9754988

8

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.

Christensen PM, Gøtzsche PC, Brøsen K. Christensen PM, et al. Among authors: brosen k. Pharmacogenetics. 1998 Dec;8(6):473-9. Pharmacogenetics. 1998. PMID: 9918130

9

Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.

Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brøsen K. Bathum L, et al. Among authors: brosen k. Pharmacogenetics. 1998 Apr;8(2):119-23. Pharmacogenetics. 1998. PMID: 10022749

10

The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.

Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brøsen K. Fjordside L, et al. Among authors: brosen k. Pharmacogenetics. 1999 Feb;9(1):55-60. doi: 10.1097/00008571-199902000-00008. Pharmacogenetics. 1999. PMID: 10208643 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

282 results

Search Page

Filters